Payment overview · 2025
General Payments
$74.04
1 reported records · 1 companies
Healthcare provider profile · identity verified
Stephen Warren Blatchly, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SIDNEY, OH · NPI 1457353963
Verified facts
What the public records show
CMS Open Payments records show Stephen Warren Blatchly, M.D. received $74.04 in general payments during 2025 across 1 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 100.0% of that reported general-payment amount.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $74.04 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $74.04 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 408 | 104 |
| Losartan Potassium | Losartan Potassium | 307 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 276 | 61 |
| Lisinopril | Lisinopril | 241 | 72 |
| Simvastatin | Simvastatin | 221 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 219 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 217 | 59 |
| Gabapentin | Gabapentin | 190 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 53 |
| Metformin Hcl | Metformin Hcl | 184 | 47 |
| Potassium Chloride | Potassium Chloride | 177 | 42 |
| Omeprazole | Omeprazole | 166 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 154 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 152 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 146 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 138 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 33 |
| Trazodone Hcl | Trazodone Hcl | 133 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 118 | 35 |
| Furosemide | Furosemide | 111 | 25 |
| Alendronate Sodium | Alendronate Sodium | 108 | 28 |
| Enalapril Maleate | Enalapril Maleate | 105 | 23 |
| Eliquis | Apixaban | 101 | 22 |
| Allopurinol | Allopurinol | 98 | 28 |
| Meloxicam | Meloxicam | 97 | 24 |
| Finasteride | Finasteride | 95 | 27 |
| Trulicity | Dulaglutide | 95 | 14 |
| Metformin Hcl Er | Metformin Hcl | 92 | 24 |
| Prednisone | Prednisone | 78 | 49 |
| Spironolactone | Spironolactone | 78 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 18 |
| Famotidine | Famotidine | 73 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 70 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 68 | 19 |
| Glimepiride | Glimepiride | 67 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 66 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 60 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 46 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 41 |
| Tramadol Hcl | Tramadol Hcl | 53 | 15 |
| Cefuroxime | Cefuroxime Axetil | 52 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 14 |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 11 |
| Montelukast Sodium | Montelukast Sodium | 47 | 16 |
| Atenolol | Atenolol | 45 | 13 |
| Donepezil Hcl | Donepezil Hcl | 44 | 12 |
| Labetalol Hcl | Labetalol Hcl | 43 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Jardiance | Empagliflozin | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | 11 |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Bumetanide | Bumetanide | 32 | 12 |
| Cephalexin | Cephalexin | 31 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 13 |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Brilinta | Ticagrelor | 27 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 18 |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Carvedilol | Carvedilol | 22 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 12 |
| Indapamide | Indapamide | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 13 |
| Fluconazole | Fluconazole | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $74.04 · 1 records | E.R. Squibb & Sons, L.L.C. | — | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error